Abstract:Dyslipidemia is a potent cardiovascular (CV) risk factor in the general population. Elevated low-density lipoprotein cholesterol (LDL-C) and/or low high-density lipoprotein (HDL-C) are well-established CV risk factors, but more precise determinants of risk include increased apoprotein B (ApoB), lipoprotein(a) [Lp(a)], intermediate and very low-density lipoprotein (IDL-C, VLDL-C; "remnant particles"), and small dense LDL particles. Lipoprotein metabolism is altered in association with declining glomerular filtration rate such that patients with non dialysis-dependent chronic kidney disease (CKD) have lower levels of HDL-C, higher triglyceride, ApoB, remnant IDL-C, remnant VLDL-C, and Lp(a), and a greater proportion of oxidized LDL-C. Similar abnormalities are prevalent in hemodialysis (HD) patients, who often manifest proatherogenic changes in LDL-C in the absence of increased levels. Patients treated with peritoneal dialysis (PD) have a similar but more severe dyslipidemia compared to HD patients due to stimulation of hepatic lipoprotein synthesis by glucose absorption from dialysate, increased insulin levels, and selective protein loss in the dialysate analogous to the nephrotic syndrome. In the dialysis-dependent CKD population, total cholesterol is directly associated with increased mortality after controlling for the presence of malnutrition-inflammation. Treatment with statins reduces CV mortality in the general population by approximately one third, irrespective of baseline LDL-C or prior CV events. Statins have similar, if not greater, efficacy in altering the lipid profile in patients with dialysis-dependent CKD (HD and PD) compared to those with normal renal function, and are well tolerated in CKD patients at moderate doses (<or=20 mg/day atorvastatin or simvastatin). Statins reduce C-reactive protein as well as lipid moieties such as ApoB, remnants IDL and VLDL-C, and oxidized and small dense LDL-C fraction. Large observational studies demonstrate that statin treatment is independently associated with a 30%-50% mortality reduction in patients with dialysis-dependent CKD (similar between HD- and PD-treated patients). One recent randomized controlled trial evaluated the ability of statin treatment to reduce mortality in type II diabetics treated with HD ("4D"); the primary end point of death from cardiac cause, myocardial infarction, and stroke was not significantly reduced. However, results of this trial may not apply to other end-stage renal disease populations. Two ongoing randomized controlled trials (SHARP and AURORA) are underway evaluating the effect of statins on CV events and death in patients with CKD (including patients treated with HD and PD). Recruitment to future trials should be given a high priority by nephrologists and, until more data are available, consideration should be given to following published guidelines for the treatment of dyslipidemia in CKD. Additional consideration could be given to treating all dialysis patients felt to be at risk of CV disease (irrespective of cholesterol level), given the safety and potential efficacy of statins. This is especially relevant in patients treated with PD, given their more atherogenic lipid profile and the lack of randomized controlled trials in this population.

Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients

Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study

Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia

The Effect of Atorvastatin on Lowering Lipids in Elderly Patients with Type 2 Diabetic Mellitus Plus Hyperlipidemia

Tissue-specific Effects of Atorvastatin on 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Expression and Activity in Spontaneously Hypertensive Rats

[Effects of Atorvastatin on Endothelium Protection in Spontaneously Hypertensive Rats].

Clinical Observation about Effection of Atorvastatin on Preventing Renal Function in Patients with Coronary Heart Disease and Diabetes Mellitus

Atorvastatin Decreased Low Density Lipoprotein Level and Improved Coronary Artery Lesion in Patients after Percutaneous Coronary Intervention

Effect of Atorvastatin on HMG -Coa Reductase Expression in Spontaneously Hypertensive Rats

Efficacy and Safety of Hybutimibe in Combination with Atorvastatin for Treatment of Hypercholesteremia among Patients with Atherosclerotic Cardiovascular Disease Risk Equivalent: A Multicenter, Randomized, Double-Blinded Phase III Study.

Effect of atorvastatin on exercise tolerance in patients with diastolic dysfunction and exercise-induced hypertension

Effects of Atorvastatin on Vascular Remodeling in Spontaneously Hypertensive Rats

Effects of Atorvastatin on Expression of Cytochrome P450 Hydroaylase in Spontaneously Hypertensive Rats

Effect of Atorvastatin on Blood Pressure in Spontaneously Hypertensive Rats

Statins for treatment of dyslipidemia in chronic kidney disease

The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients

High Dose Atorvastatin on Coronary Artery Stenosis and hs-CRP in Patients with Unstable Angina Pectoris

Effects of Long-Term Treatment with Simvastatin on Some Hemostatic Parameters in Continuous Ambulatory Peritoneal Dialysis Patients

Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial

Skew of plasma low- and high-density lipoprotein distributions to less dense subfractions in normotriglyceridemic chronic kidney disease patients on maintenance hemodialysis treatment

Aspirin Can Reduce Serum C Reactive Protein Level in Maintenance Hemodialysis Patients